由于放射性核素标记的分子影像探针具有高灵敏度、高分辨率以及可定量分析等优势,已经成为在分子水平上研究活体内病变机制和治疗效果的首选成像手段。作者概述了HER2亲合体的研究现状,主要针对放射性核素标记元素,如¹⁸F、⁶⁴Cu、⁶⁸Ga、⁹⁹Tc、¹¹¹In、¹⁸⁸Re/¹⁸⁶Re等,对HER2特异性的亲合体Z_HER2:342分子影像探针的研究进行总结和分析。

[1] 潘中允.放射性核素治疗学[M].北京:人民卫生出版社,2006:362-363.
[2] BARTLETT J,MALLON E,COOKE T.The clinical evaluation of HER-2 status:which test to use?[J].J Pathol,2003,199(4):418-423.
[3] UHLÉN M,GUSS B,NILSSON B,et al.Complete sequence of the staphylococcal gene encoding protein A.A gene evolved through multiple duplications[J].J Biol Chem,1984,259:1695-1702.
[4] MYERS J K,OAS T G.Preorganized secondary structure as an important determinant of fast protein folding[J].Nat Struct Biol,2001,8:552-558.
[5] NORD K,NILSSON J,NILSSON B,et al.A combinatorial library of an a-helical bacterial receptor domain[J].Protein Eng,1995,8(6):601-608.
[6] ARORA P,OAS T G,MYERS J K.Fast and faster:a designed variant of the B-domain of protein A folds in 3 microsec[J].Prot Sci,2004,13(4):847-853.
[7] MARCHAND P,BORGNE M L,NA Y M.Synthesis and Antileishmanial Activity of 3-(a-Azolylbenzyl)indoles[J].J Enzym Inhib Med Ch,2002,17(6):353-358.
[8] LÖFBLOM J,FELDWISCH J,TOLMACHEV V,et al.Affibody molecules:Engineered proteins for therapeutic,diagnostic and biotechnological applications[J].Febs Lett,2010,584:2670-2680.
[9] HARDY O T,HERNANDEZ-PAMPALONI M,SAFFER J R.Accuracy of fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism[J].J Clin Endocr Metab,2007,92(12):4706-4711.
[10] ERMERT J,HAMACHER K,COENEN H H.N.C.A.¹⁸F-labelled norephedrine derivatives via α-amino-propiophenones[J].J Label Compd Radiopharm,2000,43(14):1345-1363.
[11] NYE J A,SCHUSTER D M,YU W.Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-¹⁸F-FACBC in humans[J].Eu J Nucl Med,2007,48(6):1017-1020.
[12] CHEN X,PARK R,SHAHINIAN A H,et al.¹⁸F-labeled RGD peptide:initial evaluation for imaging brain tumor angiogenesis[J].Nucl Med Biol,2004,31(2):179-189.
[13] TORETSKY J,LEVENSON A,WEINBERG I N,et al.Preparation of F-18 labeled annexin Ⅴ:a potential PET radiopharmaceutical for imaging cell death[J].Nucl Med Biol,2004,31(6):747-752.
[14] SUTCLIFFE-GOULDEN J L,O'DOHERTY M J,MARSDEN P K,et al.Rapid solid phase synthesis and biodistribution of ¹⁸F-labelled linear peptides[J].Eu J Nucl Med,2002,29(6):754-759.
[15] LEMAIRE C,DAMHAUT P,PLENEVAUX A.Synthesis of fluorine-18 substituted aromatic aldehydes and benzyl bromides,new intermediates for n.c.a.fluorination[J].Appl Radiat Isotopes,1992,43(4):485-494.
[16] STOLL T,ERMERT J,OYA S,et al.Application of n.c.a. 4-fluorophenol in diaryl ether syntheses of 2-(4-fluorophenoxy)-benzylamines[J].J Labelled Compd Rad,2004,47(7):443-455.
[17] LUDWIG T,ERMERT J,COENEN H H.4-fluoroarylalky lethers via an improved synthesis of n.c.a.4-¹⁸F]fluorophenol[J].Nucl Med Biol,2002,29(2):255-262.
[18] ERMERT J,HOCKE C,LUDWIG T,et al.Comparison of pathways to the versatile synthon of no-carrier-added 1-bromo-4- fluorobenzene[J].J Labelled Compd Rad,2004,47(7):429-441.
[19] CHI D Y,KILBOURN M R,KATZENELLENBOGEN J A.Synthesis of no-carrier-added N-(fluoroalkyl) spiperone derivatives[J]. Appl Radiat Isotopes,1986,37(12):1173-1180.
[20] SHIUE C Y,WATANABE M,WOLF A P.Application of the nucleophilic substitution reaction to the synthesis of No-carrier-added fluorobenzene and other ¹⁸F-labeled aryl fluorides[J].J Labelled Compd Rad,1984,21(6):533-547.
[21] LEMAIRE C,GUILLAUME M,CHRISTIAENS L.A new route for the synthesis of fluoroaromatic substituted amino acids:no carrier added Lp- fluorophenylalanine[J].Appl Radiat Isotopes,1987,38(12):1033-1038.
[22] CHENG Z,de JESUS O P,NAMAVARI M,et al.Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific ¹⁸F-labeled protein scaffold molecules[J].J Nucl Med,2008,49(5):804-813.
[23] CHEN X,PARK R,HOU Y,et al.Micro PET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide[J].Eur J Nucl Med Mol Imaging,2004,31(8):1081-1089.
[24] CHEN X,PARK R,SHAHINIAN A,et al.Pharmacokinetics and tumor retention of ¹²⁵I-labeled RGD peptide are improved by PEGylation[J]. Nucl Med Biol,2004,31(1):11-19.
[25] LIU Z,LIU S,WANG F,et al.Noninvasive imaging of tumor integrin expression using ⁽¹⁸⁾F-labeled RGD dimer peptide with PEG(4) linkers[J].Eur J Nucl Med Mol Imaging,2009,36(8):1296-1307.
[26] CHENG Z,de JESUS O P,KRAMER D J.⁶⁴cu-labeled affibody molecules for imaging of HER2 expressing tumors[J].Mol Imaging Biol,2010,12(3):316-324.
[27] CHEN X,HOU Y,TOHME M,et al.Pegylated Arg-Gly-Asp peptide:⁶⁴Cu labeling and PET imaging of brain tumor α_v β₃-integrin expression[J].J Nucl Med,2004,45(10):1776-1783.
[28] BAUM R,ORLOVA A,TOLMACHEV V,et al.Receptor PET/CT and SPECT using an Affibody molecule for targeting and molecular imaging of HER2 positive cancer in animal xenografts and human breast cancer patients[J].J Nucl Med,2006,47:108-112.
[29] BEHR T M,SHARKEY R M,JUWEID M E,et al.Reduetion of the renal uptake of radiolabeled monoelonal antibody fragments by cationic amino acids and their derivatives[J].Cancer Res,1995,55:3825-2834.
[30] GOLDENBERG D M,JUWEID M,DUNN R M,et al.Cancer imaging with radiolabeled antibodies:new advances with technetium-99m-labeled monoelonal antibody Fab,fragments,especially CEA-San and prospects for therapy[J].J Nucl Med Technol,1997,25:18-23.
[31] HNATOWIEH D J,VIRZI F,RUSCKOWSKI M.Investigations of avidin and biotin for imaging applications[J].J Nucl Med,1987,28:1294-1302.
[32] RUSEKOWSKI M,FOGARASI M,FRITZ B,et al.Effect of endogenous biotin on the applications of streptavidin and biotin in mice[J].Nucl Med Biol,1997,24:263-268.
[33] ZHANG Y M,WANG Y,LIU N,et al.In virto investigation of tumor targeting with ⁹⁹Tc-labled antisence DNA[J].J Nucl Med,2001,42:1660-1669.
[34] LIU G,ZHANG S,HE J,et al.The influence of ehain length and base sequence on the pharmacokinetic behavior of 99mTc-morPholinos in mice[J].Q J Nucl Med,2002,46:233-243.
[35] HNATOWICH D J.Pharmacokinetics of ^{99 m}Tc-labeled oligonucleotides[J].Q J Nucl Med,1996,40:202-208.
[36] RUSEKOWSKI M,FOGARASI M,FRITZ B,et al.Effect of endogenous biotin on the applications of streptavidin and biotin in mice[J]. Nucl Med Biol,1997,24:263-268.
[37] Zhu Z,WANG Y,ZHANG Y,et al.A novel and simplified route to the synthesis of N3S chelators for ^{99 m}Tc labeling[J].Nucl Med Biol,2001,28(6):703-708.
[38] ENGFELDT T,ORLOVA A,TRAN T,et al.Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetylglycyl-glycyl-glycyl(MAG3) sequence[J].Eur J Nucl Med Mol Imaging,2007,34(5):722-733.
[39] ENGFELDT T,TRAN T,ORLOVA A,et al.99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule[J].Eur J Nucl Med Mol Imaging,2007,34(11):1843-1853.
[40] TRAN T,ENGFELDT T,ORLOVA A,et al.In vivo evaluation of cysteine-based chelators for attachment of ^99mTc to tumor-targeting Affibody molecules[J].Bioconjugate Chem,2007,18(2):549-558.
[41] TOLMACHEV V,TRAN T,ENGFELD T,et al.Preparation and evaluation of(^{99 m}Tc) maEEE-ZHER2:342 Affibody molecule for imaging of HER2 expressing tumors[J].J Lab Comp Radiopharm,2007,18:1956-1964.
[42] DEWANJEE M K,GHAFOURIPOUR A K,KAPADVANJWALA M,et al.Kinetics of hybridization of mRNA of c-myc oncogene with ¹¹¹In-labeled antisense oligodeoxynucleotide probes by high-pressure liquid chromatography[J].Bio Techniques,1994,16(5):844-850.
[43] DEWANJEE M K,GHAFOURIPOUR A K,KAPADVANJWALA M,et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model[J].J Nucl Med,1994,35(6):1054-1063.
[44] HNATOWIEH D J.Antisense and nuclear medicine[J].J Nucl Med,1999,40:693-703.
[45] ORLOVA A,TOLMACHEV V,PEHRSON R,et al.Synthetic Affibody molecules:a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors[J].Cancer Res,2007,67(5):2178-2186.
[46] BAUM R,PRASAD V,MVLLER D,et al.Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic ¹¹¹In or ⁶⁸Ga-labeled affibody molecules[J].J Nucl Med,2010,51(6):892-897.
[47] RHODES B A,LAMBERT C R,MAREK M J,et al.Re-188 labelled antibodies[J].Appl Radiat Isot,1996,47(1):7-14.
[48] SYKES T R,SOMAYAJI V V,BIER S,et al.Radiolabeling of monoelonal antibody B43.13 with Rhenium-188 for Immunoradiotherapy[J].Appl Radiat Isot,1997,48(7):899-906.
[49] BLOWER P J,KETTLE A G,O'DOHERTY M J,et al.^{99 m}Tc(V) DMSA quantitatively predicts ¹⁸⁸Re(V) DMSA distribution in patients with prostate cancer metastatic to bone[J].Eur J Nucl Med,2000,27(9):1405-1409.
[50] ORLOVA A,TRAN T A,EKBLAD T,et al.¹⁸⁶Re-maSGS-Z_HER2:342,a potential Affibody conjugate for systemic therapy of HER2-expressing tumours[J].Eur J Nucl Med Mol Imaging,2010,37(2):260-269.
[51] NORD K,GUNNERIUSSON E,RINGDAHL J,et al.Binding proteins selected from combinatorial libraries of an alphahelical bacterial receptor domain[J].Nat Biotechnol,1997,15(8):772-777.
[52] ORLOVA A,MAGNUSSON M,ERIKSSON T L,et al.Tumor imaging using a picomolar affinity HER2 binding affibody molecule[J].Cancer Res,2006,66(8):4339-4348.
[53] FORTIN M A,ORLOVA A,MALMSTROM P U,et al.Labelling chemistry and characterization of -DOTA-Z_HER2:342 Affibody molecule,a candidate agent for locoregional treatment of urinary bladder carcinoma[J].Int J Mol Med,2007,19(2):285-291.
[54] TOLMACHEV V,ORLOVA A,PEHRSON R,et al.Radionuclide therapy of HER2-positive microxenografts using a ¹⁷⁷Lu-labeled HER2-specific Affibody molecule[J].Cancer Res,2007,67:2773-2782.
[55] ORLOVA A,MAGNUSSON M,ERIKSSON T L,et al.Tumor imaging using a picomolar affinity HER2 binding affibody molecule[J].Cancer Res,2006,66(8):4339-4348.
[56] STEFFEN A C,ORLOVA A,WIKMAN M,et al.Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice[J].Eur J Nucl Med Mol Imaging, 2006,33(6):631-638.
[57] MUME E,ORLOVA A,LARSSON B,et al.Evaluation of((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody[J].Bioconjug Chem,2005,16(6):1547-1555.
[58] STEFFEN A C,ALMQVIST Y,CHYAN M K,et al.Biodistribution of ²¹¹At labeled HER-2 binding affibody molecules in mice[J].Oncol Rep,2007,17(5):1141-1147.
[59] AHLGREN S,ORLOVA A,WALLBERG H,et al.Targeting of HER2-expressing tumors using ¹¹¹In-ABY-025,a second generation Affibody molecule with a fundamentally reengineered scaffold[J].J Nucl Med,2010,51(7):1131-1138.
[60] FELDWISCH J,TOLMACHEV V,LENDEL C,et al.Design of an optimized scaffold for affibody molecules[J].J Mol Biol,2010,398(2):232-247.